The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study
Open accessAbstract
Purpose: Magnetic resonance imaging (MRI) and positron emission tomography–computed tomography (PET-CT) are important imaging techniques in multiple myeloma (MM). We conducted a prospective trial in patients with MM aimed at comparing MRI and PET-CT with respect to the detection of bone lesions at diagnosis and the prognostic value of the techniques. Patients and Methods: One hundred thirty-four patients received a combination of lenalidomide, bortezomib, and dexamethasone (RVD) with or without autologous stem-cell transplantation, followed by lenalidomide maintenance. PET-CT and MRI were performed at diagnosis, after three cycles of RVD, and before maintenance therapy. The primary end point was the detection of bone lesions at diagnosis by MRI versus PET-CT. Secondary end points included the prognostic impact of MRI and PET-CT regarding progression-free (PFS) and overall survival (OS). Results: At diagnosis, MRI results were positive in 127 of 134 patients (95%), and PET-CT results were positive in 122 of 134 patients (91%; P = .33). Normalization of MRI after three cycles of RVD and before maintenance was not predictive of PFS or OS. PET-CT became normal after three cycles of RVD in 32% of the patients with a positive evaluation at baseline, and PFS was improved in this group (30-month PFS, 78.7% v 56.8%, respectively). PET-CT normalization before maintenance was described in 62% of the patients who were positive at baseline. This was associated with better PFS and OS. Extramedullary disease at diagnosis was an independent prognostic factor for PFS and OS, whereas PET-CT normalization before maintenance was an independent prognostic factor for PFS. Conclusion: There is no difference in the detection of bone lesions at diagnosis when comparing PET-CT and MRI. PET-CT is a powerful tool to evaluate the prognosis of de novo myeloma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationKumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationInternational uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationLenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257
Self-citationEuropean Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications
Terpos, E., Kleber, M., Engelhardt, M., Zweegman, S., Gay, F., Kastritis, E., van de Donk, N. W. C. J., Bruno, B., Sezer, O., Broijl, A., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.117176 · Cited by 988
Zamagni, E., Patriarca, F., Nanni, C., Zannetti, B., Englaro, E., Pezzi, A., Tacchetti, P., Buttignol, S., Perrone, G., Brioli, A., et al. (2011) · Blood · doi:10.1182/blood-2011-06-361386 · Cited by 531
Bartel, T. B., Haessler, J., Brown, T. L. Y., Shaughnessy, J. D., van Rhee, F., Anaissie, E., Alpe, T., Angtuaco, E., Walker, R., Epstein, J., et al. (2009) · Blood · doi:10.1182/blood-2009-03-213280 · Cited by 518
Zamagni, E., Nanni, C., Patriarca, F., Englaro, E., Castellucci, P., Geatti, O., Tosi, P., Tacchetti, P., Cangini, D., Perrone, G., et al. (2007) · Haematologica · doi:10.3324/haematol.10554 · Cited by 354
Roussel, M., Lauwers-Cances, V., Robillard, N., Hulin, C., Leleu, X., Benboubker, L., Marit, G., Moreau, P., Pegourie, B., Caillot, D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8164 · Cited by 266
Self-citationUsmani, S. Z., Mitchell, A., Waheed, S., Crowley, J., Hoering, A., Petty, N., Brown, T., Bartel, T., Anaissie, E., van Rhee, F., et al. (2013) · Blood · doi:10.1182/blood-2012-08-451690 · Cited by 201
Nanni, C., Zamagni, E., Versari, A., Chauvie, S., Bianchi, A., Rensi, M., Bellò, M., Rambaldi, I., Gallamini, A., Patriarca, F. F., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3200-9 · Cited by 124
Waheed, S., Mitchell, A., Usmani, S. Z., Epstein, J., Yaccoby, S., Nair, B. P., Hemert, R. L. V., Angtuaco, E. J., Brown, T., Bartel, T. B., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.066555 · Cited by 81
The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016
Terpos, E., Dimopoulos, M. A., & Moulopoulos, L. A. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159074 · Cited by 75
Bannas, P., Hentschel, H., Bley, T. A., Treszl, A., zu Eulenburg, C., Derlin, T., Yamamura, J., Adam, G., Stübig, T., Kröger, N. M., et al. (2012) · European Radiology · doi:10.1007/s00330-012-2445-y · Cited by 63
Merz, M., Ritsch, J., Kunz, C., Wagner, B., Sauer, S., Hose, D., Moehler, T. M., Delorme, S., Goldschmidt, H., Zechmann, C. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1029 · Cited by 41
Cited by
van de Donk, N. W. C. J., Pawlyn, C., & Yong, K. L. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00135-5 · Cited by 869
Hillengass, J., Usmani, S., Rajkumar, S. V., Durie, B. G. M., Mateos, M.-V., Lonial, S., Joao, C., Anderson, K. C., García-Sanz, R., Riva, E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30309-2 · Cited by 516
Self-citationThe role of ubiquitination and deubiquitination in cancer metabolism
Sun, T., Liu, Z., & Yang, Q. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01262-x · Cited by 508
Extramedullary disease in multiple myeloma: a systematic literature review
Bladé, J., Beksac, M., Caers, J., Jurczyszyn, A., von Lilienfeld-Toal, M., Moreau, P., Rasche, L., Rosiñol, L., Usmani, S. Z., Zamagni, E., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00643-3 · Cited by 319
“[33] found that absence of EMD at diagnosis was an independent prognostic factor for longer progression-free survival (PFS; p < 0.”
BackgroundSelf-citationClinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
Oliva, S., D'Agostino, M., Boccadoro, M., & Larocca, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00001 · Cited by 291
Metadata
- Authors
- Moreau, P., Attal, M., Caillot, D., Macro, M., Karlin, L., Garderet, L., Facon, T., Benboubker, L., Escoffre-Barbe, M., Stoppa, A.-M., Laribi, K., Hulin, C., Perrot, A., Marit, G., Eveillard, J.-R., Caillon, F., Bodet-Milin, C., Pegourie, B., Dorvaux, V., Chaleteix, C., Anderson, K., Richardson, P., Munshi, N. C., Avet-Loiseau, H., Gaultier, A., Nguyen, J.-M., Dupas, B., Frampas, E., & Kraeber-Bodere, F.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-09-01
- Volume
- 35
- Issue
- 25
- Pages
- 2911-2918
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2724736336
- Cited by
- 326
- References
- 15
- FWCI
- 22.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.